 The objective of this study is to evaluate the pharmacokinetics PK of ondansetron administered as a novel modified-release formulation EUR1025 24 mg as well as the immediate-release formulation Zofran 8 mg after single and multiple oral dose administration under fasting and fed conditions based on the requirements of the respective indications. The safety profile of each treatment will also be assessed by recording the nature, severity, frequency, duration and relation to the treatment of any adverse events. 